BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36998040)

  • 1. Multimodal treatment with curative intent in a germline BRCA2 mutant metastatic ampullary adenocarcinoma: a case report.
    Mauri G; Gori V; Patelli G; Roazzi L; Rizzetto F; De Carlis L; Mariani A; Cavallari U; Prada E; Cipani T; Aquilano MC; Bonoldi E; Vanzulli A; Siena S; Sartore-Bianchi A
    World J Surg Oncol; 2023 Mar; 21(1):118. PubMed ID: 36998040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
    Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M
    Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Approach to Adenocarcinoma of the Ampulla of Vater.
    Patel M; Uboha NV
    Curr Treat Options Oncol; 2021 Sep; 22(11):103. PubMed ID: 34586537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
    Lowery MA; Kelsen DP; Stadler ZK; Yu KH; Janjigian YY; Ludwig E; D'Adamo DR; Salo-Mullen E; Robson ME; Allen PJ; Kurtz RC; O'Reilly EM
    Oncologist; 2011; 16(10):1397-402. PubMed ID: 21934105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
    Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
    Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
    Sonnenblick A; Kadouri L; Appelbaum L; Peretz T; Sagi M; Goldberg Y; Hubert A
    Cancer Biol Ther; 2011 Aug; 12(3):165-8. PubMed ID: 21613821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
    de Mestier L; Danset JB; Neuzillet C; Rebours V; Cros J; Soufir N; Hammel P
    Endocr Relat Cancer; 2016 Oct; 23(10):T57-67. PubMed ID: 27511924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    Blair AB; Groot VP; Gemenetzis G; Wei J; Cameron JL; Weiss MJ; Goggins M; Wolfgang CL; Yu J; He J
    J Am Coll Surg; 2018 Apr; 226(4):630-637.e1. PubMed ID: 29309945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    Simmons AD; Nguyen M; Pintus E
    BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer.
    Yildirim HC; Ismayilov R; Akyildiz A; Guven DC; Abdurrahimli N; Dizdar O; Yalcin S
    Anticancer Drugs; 2023 Nov; 34(10):1190-1192. PubMed ID: 36729128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant.
    Sunami T; Yamada A; Kondo T; Kanai M; Nagai K; Uchida Y; Yokode M; Matsumori T; Uza N; Murakami H; Yamada T; Muto M
    Pancreas; 2022 Oct; 51(9):1258-1262. PubMed ID: 37078954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
    Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
    Ferrone CR; Levine DA; Tang LH; Allen PJ; Jarnagin W; Brennan MF; Offit K; Robson ME
    J Clin Oncol; 2009 Jan; 27(3):433-8. PubMed ID: 19064968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
    Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
    Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
    Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
    Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.